Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-LAG-3 + pomalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of an anti-LAG-3 monoclonal antibody, pomalidomide, and dexamethasone. Anti-LAG-3 antibodies are immune checkpoint inhibitors that block the Lymphocyte Activation Gene-3 (LAG-3) receptor on T cells. By inhibiting LAG-3, these antibodies restore T cell function and enhance the immune system's ability to attack tumor cells[1][2][5]. Pomalidomide is an immunomodulatory small molecule that enhances T-cell and natural killer (NK) cell-mediated immunity and inhibits angiogenesis. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. This combination may be investigated for use in hematologic malignancies such as multiple myeloma or other cancers where immune modulation is beneficial.
- Brand names
- Pomalyst
- Other names
- anti-LAG-3 + pomalidomide + dexamethasone
02
Targets
GR (Glucocorticoid receptor)CRBN (Cereblon)
Beyond the preview
Go deeper on anti-LAG-3 + pomalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-LAG-3 + pomalidomide + dexamethasone.